Journal of Biological Chemistry
Volume 295, Issue 42, 16 October 2020, Pages 14445-14457
Journal home page for Journal of Biological Chemistry

Immunology
Atypical TRAV1-2 T cell receptor recognition of the antigen-presenting molecule MR1

https://doi.org/10.1074/jbc.RA120.015292Get rights and content
Under a Creative Commons license
open access

MR1 presents vitamin B–related metabolites to mucosal associated invariant T (MAIT) cells, which are characterized, in part, by the TRAV1-2+ αβ T cell receptor (TCR). In addition, a more diverse TRAV1-2 MR1-restricted T cell repertoire exists that can possess altered specificity for MR1 antigens. However, the molecular basis of how such TRAV1-2 TCRs interact with MR1–antigen complexes remains unclear. Here, we describe how a TRAV12-2+ TCR (termed D462-E4) recognizes an MR1–antigen complex. We report the crystal structures of the unliganded D462-E4 TCR and its complex with MR1 presenting the riboflavin-based antigen 5-OP-RU. Here, the TRBV29-1 β-chain of the D462-E4 TCR binds over the F′-pocket of MR1, whereby the complementarity-determining region (CDR) 3β loop surrounded and projected into the F′-pocket. Nevertheless, the CDR3β loop anchored proximal to the MR1 A′-pocket and mediated direct contact with the 5-OP-RU antigen. The D462-E4 TCR footprint on MR1 contrasted that of the TRAV1-2+ and TRAV36+ TCRs' docking topologies on MR1. Accordingly, diverse MR1-restricted T cell repertoire reveals differential docking modalities on MR1, thus providing greater scope for differing antigen specificities.

: Antigen presentation
MHC-related molecule (MR1)
MAIT
atypical MAIT TCR
protein structure
immunology
major histocompatibility complex (MHC)
crystal structure
receptor structure-function
T-cell receptor (TCR)

Cited by (0)

Author contributions—W. A., E. W. M., J. L. N., and D. M. L. formal analysis; W. A. and J. L. N. investigation; W. A. and J. R. writing-original draft; W. A., D. P. F., D. M. L., and J. R. writing-review and editing; M. L. S.-R. methodology; J. L. N. and D. M. L. project administration; A. H. W. and M. D. N. data curation; L. L., D. P. F., J. M., and J. R. resources; J. M., D. P. F., D. M. L., and J. R. funding acquisition; D. M. L. and J. R. conceptualization; J. R. supervision.

Funding and additional information—This work was supported by Australian National Health and Medical Research Council (NHMRC) Grants 1125493 and 1113293 and Australian Research Council (ARC) Grant CE140100011. D. P. F. is an NHMRC Senior Principal Research Fellow (1117017), J. L. N. is an ARC Future Fellow (FT160100074), J.R. is an Australian ARC Laureate Fellow.

Conflict of interest—J. R., J. M., L. L., and D. P. F. are named inventors on patent applications (PCT/AU2013/000742, WO2014005194) (PCT/AU2015/050148, WO2015149130) involving MR1 ligands for MR1-restricted MAIT cells owned by University of Queensland, Monash University, and University of Melbourne.

Abbreviations—The abbreviations used are:

    MAIT

    mucosal associated invariant T

    TCR

    T cell receptor

    CDR

    complementarity-determining region

    Ag

    antigen

    SPR

    surface plasmon resonance

    BSA

    buried surface area

    rmsd

    root mean square deviation.